A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors

@article{Hartmann2004ART,
  title={A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors},
  author={J. Hartmann and L. Fels and S. Knop and H. Stolte and L. Kanz and C. Bokemeyer},
  journal={Investigational New Drugs},
  year={2004},
  volume={18},
  pages={281-289}
}
  • J. Hartmann, L. Fels, +3 authors C. Bokemeyer
  • Published 2004
  • Medicine
  • Investigational New Drugs
  • This study evaluates the degree of kidney damageduring cisplatin/ifosfamide-based combinationchemotherapy and its possible prevention byamifostine. Thirty-one patients with solid tumorsstratified according to pretreatment were randomizedto receive VIP- or TIP-chemotherapy with or withoutamifostine (910 mg/m2) given as a short infusion priorto cisplatin. Chemotherapy consisted of cisplatin(50 mg/m2), ifosfamide (4 g/m2) and either etoposide(500 mg/m2) (= VIP) or paclitaxel (175 mg/m2) (= TIP… CONTINUE READING
    67 Citations

    Figures, Tables, and Topics from this paper

    Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
    • 45
    • PDF
    Risk analysis for cisplatin-induced nephrotoxicity during first cycle of chemotherapy
    • 5
    • PDF
    Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
    • 4
    Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    • B. Ali, M. A. Al Moundhri
    • Chemistry, Medicine
    • Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
    • 2006
    • 290
    Amifostine Protects Against Cisplatin-Induced Nephrotoxicity in a Child with Medulloblastoma
    • M. Hayek
    • Medicine
    • Pediatric hematology and oncology
    • 2003
    • 5

    References

    SHOWING 1-10 OF 39 REFERENCES
    Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    • G. Kemp, P. Rose, +6 authors J. Glick
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 411
    • PDF
    Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
    • J. Schiller, B. Storer, +4 authors W. Berry
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 79
    High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma
    • 60
    Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    • 12
    Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
    • 81
    • PDF
    Long-term effects of chemotherapy in patients with testicular cancer.
    • 128
    Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
    • 17
    Platinum organ toxicity and possible prevention in patients with testicular cancer
    • 179